Next-generation sequencing (NGS) and other genomic analysis technologies can help pharmaceutical and biotech researchers better understand the genetic variants associated with various diseases. These insights can accelerate drug discovery efforts and support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to drug discovery and development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for detailed biomarker information and companion diagnostics is increasing.Learn More
NGS can help pharmaceutical researchers and drug developers explore genomic variation. This can inform drug target discovery, validation, and clinical development.Learn More
Understand how variations in the human genome affect our response to medications. Pharmacogenomics (PGx) research can ultimately help maximize the benefits of treatment plans while reducing health care costs.Learn More About PGx
A groundbreaking international clinical study has succeeded in integrating imaging, multiomic technologies, and data analysis into a powerful drug discovery engine. The Global Genomics Group (G3) has demonstrated the value of its novel approach, with the introduction of a new diagnostic and several drug candidates in development with pharmaceutical partners.Read Article
Pharmaceutical and biotech scientists leading targeted drug discovery efforts have traditionally focused on inhibiting or modulating the function of abnormal proteins. But diseases could also potentially be treated in the future by controlling gene expression. In this podcast episode, Dr. Eric R. Olson of Syros Pharmaceuticals explains how epigenomics is enabling a paradigm shift in drug discovery.Listen to the Podcast